MedPage Today
She's screened for diabetes at a BMI of 23 but denied a GLP-1 until 30. She argues insurers should use ethnicity-adjusted thresholds that guidelines already publish.
Recap by typeshit. Full story at MedPage Today.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
Bloomberg reports that employer coverage of GLP-1 weight loss drugs is shrinking, leaving fewer US workers with access through their health plans.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
A short post on how the two semaglutide shots differ: Ozempic is used for A1C, Wegovy for weight and metabolic health. It is a basic overview.
A new Journal of the American Chemical Society study describes a solid-state method for finding and quantifying peptide biomarkers in diluted human serum.
Loading…